Summary & Overview
HCPCS J7608: Acetylcysteine Inhalation Solution, Unit Dose, Per Gram
HCPCS Level II code J7608 designates acetylcysteine inhalation solution, an FDA-approved, non-compounded unit-dose mucolytic product billed per gram and intended for administration via durable medical equipment. This code matters nationally as it standardizes billing for inhaled acetylcysteine in home and outpatient DME settings, affecting coverage decisions, claims processing, and access to inhalation therapy for patients with conditions characterized by viscous airway secretions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, expected sites of service, and the clinical context for use. The publication provides benchmarks and coding guidance coverage trends, and policy implications relevant to national payers, including typical billing practices and areas where payer-specific rules may affect reimbursement and prior authorization requirements.
The content also outlines what to expect in the claims line for DME-delivered inhalation medication and directs readers to follow payer-specific billing rules and medical necessity policies. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7608 describes acetylcysteine inhalation solution, an FDA-approved, non-compounded final product supplied in unit dose form and billed per gram. The code identifies the medication when it is administered through durable medical equipment (DME) for inhalation therapy.
Service Type: Inhalation mucolytic medication administration
Typical Site of Service: Home or outpatient setting using DME
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with thick, inspissated pulmonary secretions or an acetaminophen overdose requiring inhaled mucolytic therapy administered via durable medical equipment. The most common scenario is a patient with chronic bronchitis, cystic fibrosis, bronchiectasis, or acute lower respiratory infection with retained secretions who receives inhaled acetylcysteine solution (J7608) in unit-dose form through a nebulizer provided as DME at home or in an outpatient infusion/respiratory clinic. The clinical workflow begins with a prescribing clinician (pulmonologist, emergency physician, pediatrician, or primary care provider) evaluating respiratory status and ordering inhaled acetylcysteine for mucolysis. A DME supplier dispenses the FDA-approved unit-dose inhalation solution and provides patient education on nebulizer assembly, dosing, administration technique, and cleaning. Nursing or respiratory therapy may supervise initial administration in clinic or hospital discharge teaching. Follow-up visits or telehealth encounters assess treatment response, symptom improvement, and need for ongoing therapy or alternative interventions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply. |